SIRT1 and cancer: Finally, given that SAMHD1 depletion and proteasomal degradation sensitizes cancer cells to IR, PARP inhibitor, and other DSB-inducing agents69, our findings provide mechanistic rationale for targeting the end resection function of SAMHD1 through SIRT1 inhibition as an adjunct to DSB-inducing agents for cancer therapy.